Pitavastatin
Проводит Kowa Research Europe
Страница компанииOpen-Label, Long-Term (1 Year) Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00325780/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1355 чел. во всех странах исследования.
- Центров в реестре: 25 в 4 городах. Список — ниже на странице.
- Плановая дата окончания (11.2007) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 5
Критерии включения
- Patients have completed 12 weeks of treatment in Study NK-104-301 (NCT00249249) or NK-104-302 (NCT00309777)
- Patients who have not developed any treatment emergent and, in the opinion of the investigator, related adverse event (AE) of clinical significance where the investigator is uncomfortable with continuing the patient on therapy with pitavastatin.
- Patients who have been following a fat and cholesterol restrictive diet.
Критерии невключения
- Any conditions which may cause secondary dyslipidemia should be reassessed at the beginning of the follow-up study.
- Uncontrolled diabetes mellitus should be reassessed at the beginning of the follow-up study.
- Abnormal pancreatic, liver, or renal function
- Abnormal serum ALAT/SGPT/ALT, ASAT/SGOT/AST, or creatine kinase (CK) above the pre-specified level
- Significant heart disease
Источник: ClinicalTrials.gov, NCT00325780 · запись обновлена в реестре 2 февраля 2010.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 1
- Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — Baseline to 52 Weeks
Цель исследования
This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.
Где проходит
25 центров в 4 городах- Central Clinical Hospital 1 of RZD
- City Clinical Hospital 23
- City Clinical Hospital 64
- Federal State Institution Out-Patient Clinic 3 of Russian Federation of President’s Management
- Moscow City Clinical Hospital 68
- Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy
- State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Department of Internal Diseases and Rheumatology based at City Clinica
- State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40
- State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department #1 based at City Clinical Hospital # 52
- State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Development�, Department of Polyclinic Therapy based at Diagnostic Center # 1
- State Educational Institution of Higher Professional Education “Russian State Medical University of Federal Agency of Health Care and Social Development�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Depar
- State Institution “Research Institute of Physical and Chemical Medicine� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29
- State Institution “Russian Cardiology Research Complex� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis
- State Research Center for Preventive Medicine
- Central Medical Unit 122, St. Pb
- Clinical Hospital of Russian Academy of Sciences
- Consulting and Diagnostic Center 85
- Krestovsky Island Medical Institute
- St. Petersburg State Medical Institution “Out-patient Clinic # 109�
- St. Petersburg State Medical Institution “Pokrovskaya City Hospital�, Cardiology Department #2
- State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Chair and Department of Faculty Therapy
- State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Institute of Cardiovascular Diseases
- СПб ГБУЗ «Городская Покровская больница»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00325780 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.